30 Dec 2013 10:53
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Imperial Innovations Group Share News (IVO)
IVO Share
Price
IVO Share
News
IVO Share
Chat
IVO Share
Trades
IVO
Live RNS
IVO Share
Charts
IVO Broker
Ratings
IVO Directors
Deals
IVO Financial
Diary
IVO
Fundamentals
IVO Short
Positions
IVO
Media
Imperial Innovations Group Information
- There is currently no data for IVO
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.Imperial Innovations celebrates investment momentum
Mon, 24th Oct 2016 15:04
(ShareCast News) - Imperial Innovations Group noted on Monday that its portfolio company, Veryan Medical, has completed enrolment into the MIMICS-2 clinical study of its BioMimics 3D Self-Expanding Stent System.The AIM-traded firm said the MIMICS-2 study is a prospective, multicentre, interventional study designed to evaluate the safety and effectiveness of Veryan's patented three dimensional helical stent in the treatment of patients with symptomatic femoropopliteal disease.It said the study is being conducted under a US Food and Drug Administration Investigational Device Exemption (IDE), with Japanese Pharmaceuticals and Medical Devices Agency concurrence under the 'Harmonisation By Doing' initiative, in order to provide safety and effectiveness data to support future marketing applications for BioMimics 3D in both the US and Japan.BioMimics 3D has previously been awarded the CE Mark and is actively being sold across Europe, Imperial's board reported.Enrolment in the MIMICS-2 study concluded with a total of 271 patients enrolled across 47 investigational sites in Germany, the US and Japan.As at 31 July 2016, Imperial Innovations had a 46.1% interest in the issued share capital of Veryan with a net investment carrying value of £26.5m."Completion of enrolment into the MIMICS-2 is an important milestone for Veryan on its path to the global commercialisation of its unique stent technology," said Imperial Innovations chief investment officer Dr Nigel Pitchford."We are very pleased with the speed at which enrolment has been completed, which is a testament to the investigating physicians' enthusiasm for recruiting patients and the efficiency of the Veryan team."
More News
17 Oct 2013 07:07
Thursday tips round-up: Imperial Innovations, Vertu Motors
Imperial Innovations has the right to take interesting discoveries from Imperial College London and package them up into companies that eventually can be floated or sold. The majority of its 92 investments are in pharmaceuticals; one of the most promising, Circassia, is well into clinical trials for
Read more16 Oct 2013 11:25
Imperial Innovations portfolio value rises as companies near IPO
Imperial Innovations accompanied news of a full year rise in its portfolio value with the announcement of a Nasdaq flotation for portfolio company Oxford Immunotec. The university spin-out group said had "a number" of companies in its portfolio also ready for initial public offering (IPO) or trade
Read more16 Oct 2013 10:36
17 Jul 2013 10:39
Innovations CEO steps down
Technology commercialisation and investment group Imperial Innovations confirmed that Chief Executive Susan Searle has stepped down after 11 years in the role. Chief investment officer Russ Cummings, who has been a director since the group's flotation in 2006, has taken over as CEO with immediate
Read more29 Apr 2013 12:15
Kelsey Lynn appointed Director of Technology Ventures at Imperial Innovations Group
AIM-listed technology commercialisation and investment group Imperial Innovations Group has reported that that Kelsey Lynn has joined as Director of Technology Ventures with immediate effect. Lynn spent the last twelve years in California, working in new technology development and venture capital
Read more22 Mar 2013 08:44
Imperial Innovations reports strong progress in top three portfolio companies
Imperial Innovations, a technology commercialisation and investment group, on Friday reported 'really good' progress in its top three portfolio companies in its half year results. The firm said that in the six months ended January 31st its top three portfolio companies, namely Circassia, Nexeon an
Read more22 Feb 2013 11:40
Imperial Innovations reports that Nexeon signed partnership with WACKER
AIM-listed technology commercialisation and investment group Imperial Innovations has announced that portfolio company Nexeon, a battery materials and licensing company, has signed a strategic partnership agreement with German chemical company WACKER Chemie AG (WACKER). The group reported that WAC
Read more23 Jan 2013 08:21
Imperial Innovations invests 1.5m pounds in tech firm Semetric
Technology commercialisation and investment group Imperial Innovations has invested 1.5m pounds in technology firm Semetric, the company behind global music analytics specialist, Musicmetric. The group said that the investment was part of a £3m funding round which also included its existing investo
Read more5 Oct 2012 13:18
Imperial Innovations rises to university challenge
A change in the fair value of investments held by Imperial Innovations, the hot-house for technology and healthcare ideas from Britain's universities, saw full year profits surge. Revenues eased, however, reflecting the continuing difficult economic environment. Total revenues in the year to the en
Read more